Abigail Brooks, MA

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

More than half of patients with RA or PsA without obesity exhibited steatosis despite having low disease activity, with no differences observed based on methotrexate use and dosage.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.

Findings from a 2-year extension of the Plants for Joints randomized controlled trial show promise for the long-term benefits of diet, physical activity, and stress management in RA.

Findings underscore the impact of socioeconomic factors on disease management and therapeutic outcomes in patients with rheumatoid arthritis from different socioeconomic classes.

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

Study results highlight the impact of continuous glucose monitoring on glucose control and HbA1c improvements in patients with type 2 diabetes, regardless of treatment regimen.

Teva Pharmaceuticals’ launch of an authorized generic of liraglutide injection 1.8 mg (Victoza) for type 2 diabetes makes it the first-ever generic GLP-1.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Participants assigned to a 4-day energy balance diet plus oral bisphenol A administration at 50 μg/kg body weight experienced significant decreases in peripheral insulin sensitivity.

New phase 1/2 data suggest VX-880 islet cell therapy may restore physiological islet function and glycemic control in patients with T1D, potentially eliminating the need for insulin use.

Loftus explains the significance of IL-23 and Th17 in IBD and key trial data supporting the FDA approval of risankizumab in ulcerative colitis.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

Ross-Driscoll explains how disparities in the liver transplant process begin prior to waitlisting and how findings from her research on referral and evaluation may inform interventions.

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Findings suggest machine learning models may have promising utility in IgAN, highlighting the superior diagnostic performance of certain models versus standard logistic regression.

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

Interim analyses of a pair of phase 2b studies highlight the IBAT inhibitor’s potential in adults with primary biliary cholangitis and primary sclerosing cholangitis.

The network meta-analysis found tenofovir disoproxil fumarate was more likely to achieve virologic response at week 48, while entecavir was superior for 48-week biochemical response.

Lower free thyroxine levels were linked to worse renal outcomes in patients with IgAN, and free thyroxine with tubular atrophy/interstitial fibrosis had high predictive value for IgAN prognosis.

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Survey results called attention to gaps in physicians’ clinical knowledge of IgAN, with incorrect responses prevalent among both specialists and generalists.

Findings highlight significant improvements in psychological constructs related to pain and quality of life following an 8-week intervention with hyperbaric oxygen therapy.